15th International Cardiovascular Reasearch Meeting

PROGRAM MERYTORYCZNY

Zapraszamy do zapoznania się ze szczegółami programu.

09:00 - 09:05

Opening speech

Jacek Kubica (PL)

09:05 - 09:25

Opening Lecture - How to optimise antithrombotic therapy in cardiogenic shock?

Diana A. Gorog (UK)

09:25 - 09:30

Break

09:30 - 11:30

SESSION 1

09:30 - 09:45

Predictors of in-hospital clinical outcome in COVID-19 patients

Leszek Gromadziński (PL)

09:45 - 10:00

Determinants of anti-SARS-CoV-2 antibodies after vaccination

Magdalena Krintus (PL)

10:00 - 10:15

Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized non-intesive-care COVID-19 pa-tients - SIRIO randomized study

Przemysław Podhajski (PL)

10:15 - 10:30

Metformin use in patients hospitalized with COVID-19

Paul A. Gurbel (USA)

10:30 - 10:45

IMPACT of PCSK9 inhibition on clinical outcome in patients with COVID-19 (The IMPACT COVID 19 - SIRIO 5 randomized study)

Eliano P. Navarese (IT)

10:45 - 11:00

Post-COVID-19 rehabilitation

Małgorzata Ostrowska (PL)

11:00 - 11:30

DISCUSSION

11:30 - 11:45

Break

11:45 - 13:45

SESSION 2

11:45 - 12:00

NSTE-ACS ESC Guidelines do not recommend pretreatment with P2Y12 Inhibitor

Piotr Niezgoda (PL)

12:00 - 12:05

NSTE-ACS ESC Guidelines do not recommend pretreatment with P2Y12 Inhibitor. A Contrarian View

Wiktor Kuliczkowski (PL)

12:15 - 12:30

NSTE-ACS ESC Guidelines recommend prasugrel as the preferred P2Y12 Inhibitor

Piotr Adamski (PL)

12:30 - 12:45

NSTE-ACS ESC Guidelines recommend prasugrel as the preferred P2Y12 Inhibitor. A Contrarian View

Michael Savage (USA)

12:45 - 13:00

Dual antiplatelet therapy in acute coronary syndrome – a comparison of clopidogrel, prasugrel and ticagrelor – a Metaanalysis

Eliano P. Navarese (IT)

13:00 - 13:15

Dual antiplatelet therapy in acute coronary syndrome – a comparison of clopidogrel, prasugrel and ticagrelor – the PL- ACS Registry

Jacek Kubica (PL)

13:15 - 13:45

DISCUSSION

13:45 - 14:00

Break

14:00 - 16:00

SESSION 3

14:00 - 14:15

Use of ultra-thin strut sirolimus-eluting coronary stents in acute coronary syndrome – is it a way to reduce risk of throbosis?

Tommaso Gori (D)

14:15 - 14:30

Microcirculation assessment in patients with acute coronary syndrome undergoing PCI

Jacek Legutko (PL)

14:30 - 14:45

Pharmacodynamics of cangrelor in cardiogenic shock – clinical implications

Jolanta Siller-Matula (A)

14:45 - 15:00

Is personalized pharmacotherapeutic approach closed for acute coronary syndrome?

Udaya Tantry (USA)

15:00 - 15:15

Prasugrel or ticagrelor in acute coronary syndrome – is a tailored choice justified? – the PL-ACS registry

Jacek Kubica (PL)

15:15 - 15:30

Diurnal variability of platelet aggregation in patients with myocardial infarction treated with prasugrel and ticagrelor

Piotr Adamski (PL)

15:30 - 16:00

DISCUSSION

16:00 - 16:15

Break

16:15 - 18:00

SESSION 4 - Young Researchers Session: COVID-19 - a Challenge for the Healthcare System

Vaccination against COVID-19 - does it affect the course of the disease and the severity of symptoms?
Zuzanna Głowacka
Views of the academic community on actively combating the threat of COVID-19
Bartosz Majchrzak
Are facts enough? Convincing the academic community to methods of fighting COVID-19
Mikołaj Woźnica
Can the COVID-19 vaccine save somebody's life?
Piotr Kolterman
The prevalence of the post-COVID syndrome and the assessment of functioning in chronic illness
Aleksandra Białczyk
COVID-19 facts and myths - verification of the public's knowledge about COVID-19 disease
Dale Verghese
The impact of COVID-19 pandemic on mortality of hospitalized patients without COVID-19
Patryk Rogaczewski
Comparison of the angiographic image of the heart in patients with acute coronary syndrome with vs. without COVID-19
Karolina Skonieczna

09:00 - 09:20

The role of ACE-inhibitors in cardiovascular continuum: focus on the SMILE project

Claudio Borghi (IT)

09:20 - 09:30

Break

09:30 - 11:30

SESSION 5

09:30 - 09:45

Impact of COVID-19 pandemic on out-of- hospital cardiac arrest occurence (OSCAR-POL registry)

Jakub Ratajczak (PL)

09:45 - 10:00

Epidemiology, management and survival rate of out-of-hospital cardiac arrest

Klaudiusz Nadolny (PL)

10:00 - 10:15

Imapct of therapeutic hypothermia after a sudden cardiac arrest in patients with myocardial infarction

Agata Sobczyk (PL)

10:15 - 10:30

Effectiveness of ticagrelor in comatose survivors of out-of-hospital cardiac arrest undergoing PCI and therapeutic hypothermia

Marek T. Tomala (PL)

10:30 - 10:45

Effectiveness of ticagrelor in comatose survivors of out-of-hospital cardiac arrest undergoing PCI and therapeutic hypothermia (UNICORN study)

Julia M. Umińska (PL)

10:45 - 11:00

Stent thrombosis in comatose survivors of out-of-hospital cardiac arrest undergoing PCI and therapeutic hypothermia (ST-OHCA study)

Martin Rauber (SLO)

11:00 - 11:30

DISCUSSION

11:30 - 11:45

Break

11:45 - 13:45

SESSION 6

11:45 - 12:00

Recombinant Human Lecithin Cholesterol Acyl transferase in Acute ST-Elevation Myocardial Infarction: Results of REAL-TIMI 63B

Marc Bonaca (USA)

12:00 - 12:15

Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention in patients with prior CABG (The TWILIGHT-CABG study)

Robert Gil (PL)

12:15 - 12:30

Low-dose prasugrel or clopidogrel for elderly patients with acute coronary syndrome? (A sub-study of the ELDERLY ACS 2 trial)

Stefano De Servi (IT)

12:30 - 12:45

Revascularization in STEMI patients with multi-vessel disease (multicenter registry)

Wojciech Wojakowski (PL)

12:45 - 13:00

Efficacy and Safety of the Oral Factor XIa Inhibitor. Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction. Main Results of PACIFIC-AMI TRIAL

Andrzej Budaj (PL)

13:00 - 13:15

PCI versus CABG for treatind in-stent restenosis in unprotected left main (LM-DRAGON registry)

Wojciech Wańha (PL)

13:15 - 13:45

DISCUSSION

13:45 - 14:00

Break

14:00 - 16:05

SESSION 7

14:00 - 14:15

Virtual reality-enhanced rehabilitation in patients with coronary artery disease